Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. (Q37495292)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 May 2009

Language	Label	Description	Also known as
English	Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.	scientific article published on 25 May 2009

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

head and neck squamous cell carcinoma

0 references

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Y Koh

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

T M Kim

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Y K Jeon

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

T-K Kwon

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

S-H Lee

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

D-W Kim

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

H-G Wu

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

C-S Rhee

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

M-W Sung

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

C W Kim

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

K H Kim

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

D S Heo

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

25 May 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1414-1419

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19468031%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

Class III -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

Psoriasin (S100A7) expression and invasive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP002

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37495292&oldid=2089133931"